Skip to main content
OpenTrials

Clinical trial condition

Recurrent Plasma Cell Myeloma

Explore clinical trials studying Recurrent Plasma Cell Myeloma. Study availability and eligibility vary by location and protocol.

58 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Plasma Cell Myeloma trial results

Completed

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01989598

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Foothills Hospital Calgary, Alberta, Canada
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Kingston Health Sciences Centre Kingston, Ontario, Canada
View Trial Details
Completed

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

NCT01822509

Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Blood Protein Disorders, Bone Marrow Diseases, +44 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 13 locations
View Trial Details
Completed

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

NCT00068718

Conditions
Blast Crisis, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blood Protein Disorders, +38 more
Locations
  • VA Puget Sound Health Care System Seattle, Washington, United States
  • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States
  • Universitaet Leipzig Leipzig, Germany
  • University of Torino Torino, Italy
View Trial Details
Completed

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

NCT00789776

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, +49 more
Locations
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
  • Children's Hospital of Wisconsin Milwaukee, Wisconsin, United States
  • Froedtert and the Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details

Related conditions